This Bull Market Indicator called NVDA at $116

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

Ronald Kirk Huntsman net worth and biography

Ronald Huntsman Biography and Net Worth

CEO of Vivos Therapeutics

R. Kirk Huntsman is a co-founder of our company and has served as our Chief Executive Officer and a director since September 2016. In June 2020, he was elected Chairman of the Board by our board of directors. In 1995, he founded Dental One (now Dental One Partners), which, as President and Chief Executive Officer he grew to become one of the leading DSOs (dental service organizations) in the country, with over 165 practices in 15 states. After a successful sale of Dental One to MSD Capital in 2008 and subsequent merger in 2009 with Dental Care Partners, Mr. Huntsman was appointed in 2010 as Chief Executive Officer of ReachOut Healthcare America, a Morgan Stanley Private Equity portfolio company. In 2012, he founded Xenith Practices, LLC, a DSO focused on rolling up larger independent general dental offices, which were sold in 2015. From January 2014 to September 2015, Mr. Huntsman founded and served as the Chief Executive Officer of Ortho Ventures, LLC, a US distributor of certain pediatric oral appliances with applications for pediatric sleep disordered breathing. Since November 2015, he has served as the Chief Executive Officer of First Vivos, Inc., which is now our wholly owned subsidiary. He was also a founding member of the Dental Group Practice Association (DGPA), now known as the Association of Dental Support Organizations (ADSO). He is the father of Todd Huntsman. He holds a BS degree in finance from Brigham Young University.

What is Ronald Kirk Huntsman's net worth?: The estimated net worth of Ronald Kirk Huntsman is at least $9,999.40 as of June 20th, 2023. Mr. Huntsman owns 3,460 shares of Vivos Therapeutics stock worth more than $9,999 as of November 20th. This net worth estimate does not reflect any other investments that Mr. Huntsman may own. Learn More about Ronald Kirk Huntsman's net worth.
How do I contact Ronald Kirk Huntsman?: The corporate mailing address for Mr. Huntsman and other Vivos Therapeutics executives is , , . Vivos Therapeutics can also be reached via phone at 866-908-4867 and via email at [email protected]. Learn More on Ronald Kirk Huntsman's contact information.
Has Ronald Kirk Huntsman been buying or selling shares of Vivos Therapeutics?: Ronald Kirk Huntsman has not been actively trading shares of Vivos Therapeutics during the last quarter. Most recently, on Tuesday, June 20th, Ronald Kirk Huntsman bought 560 shares of Vivos Therapeutics stock. The stock was acquired at an average cost of $13.25 per share, with a total value of $7,420.00. Following the completion of the transaction, the chief executive officer now directly owns 3,460 shares of the company's stock, valued at $45,845. Learn More on Ronald Kirk Huntsman's trading history.
Who are Vivos Therapeutics' active insiders?: Vivos Therapeutics' insider roster includes Bradford Amman (CFO), and Ronald Huntsman (CEO). Learn More on Vivos Therapeutics' active insiders.

Ronald Kirk Huntsman Insider Trading History at Vivos Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/20/2023	Buy	560	$13.25	$7,420.00	3,460
6/16/2023	Buy	600	$13.50	$8,100.00	2,900
6/14/2023	Buy	400	$12.25	$4,900.00	2,300
12/23/2022	Buy	800	$12.50	$10,000.00	1,900
5/31/2022	Buy	320	$50.75	$16,240.00	940
9/21/2021	Buy	200	$107.75	$21,550.00
8/17/2021	Buy	200	$75.00	$15,000.00	420
12/23/2020	Buy	40	$181.75	$7,270.00

Ronald Kirk Huntsman Buying and Selling Activity at Vivos Therapeutics

Vivos Therapeutics Company Overview

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

Today's Range

Now: $2.81

$2.81

50 Day Range

MA: $2.78

$2.29

$4.13

2 Week Range

Now: $2.81

$1.91

$48.79

Volume

292 shs

Average Volume

477,662 shs

Market Capitalization

$13.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

7.71